Objective: Many studies have reported the role of glutathione S-transferase Mu 1 (GST M1) polymorphism with ovary cancer risk, but the results remained controversial.
Materials and methods: To derive a more precise estimation of the relationship, a meta-analysis was performed. Odds ratios (ORs) with 95% confidence intervals (CIs) were estimated to assess the association between GSTM1 polymorphism and ovary cancer risk. A total of 11 studies including 2709 cases and 3599 controls were also involved in this meta-analysis.
Results: When all the eligible studies were pooled into this meta-analysis, no significant association between ovary cancer risk and GSTM1 polymorphism was found (OR = 1.010, 95% CI = 0.911-1.121, P heterogeneity = 0.174, P = 0.848).
Discussion: Our meta-analysis supports that the GSTM1 polymorphism is not contributed to the risk of ovary cancer from currently available evidence.